The study is a placebo controlled, double blinded, cross-over design with three doses of CX717 compared to placebo. Depending on the pace of subjects being enrolled, Cortex at this point believes that top-line data will be available from this study by the end of June, 2008.
If the German Ampakine studies are successful, pre-surgical or post- surgical administration of CX717 could improve the safety margin for giving these analgesic agents, which would provide a valuable tool for anesthesiologists and surgeons to optimize pain management in surgical patients. This would be true in high risk surgical patients such as those over the age of sixty-five, those with a history of sleep apnea, respiratory illnesses or obese patients.